Filing Flows › Comparisons › IVVD vs CHRS
Invivyd vs Coherus Oncology: IVVD and CHRS compared
Invivyd is the larger company: $14.3M of revenue in its latest quarter (Q2 2026) against $14.3M for Coherus Oncology (Q3 2026). Coherus Oncology is growing faster (+23% against +21% a year earlier). Coherus Oncology is more profitable, with an operating margin of -235.7% against -320.8%.
Where the money goes: IVVD and CHRS
Invivyd (IVVD) · Q2 2026
Invivyd, Q2 2026: revenue $14.3M (+21% year over year), operating margin -320.8%, net loss $44.4M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
Coherus Oncology (CHRS) · Q3 2026
Coherus Oncology, Q3 2026: revenue $14.3M (+23% year over year), operating margin -235.7%, net loss $39.3M, operating cash flow −$34.0M. The chart follows the revenue to costs, profit and cash.
| Invivyd (IVVD) | Coherus Oncology (CHRS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $14.3M | $14.3M |
| Revenue growth, Y/Y | +21% | +23% |
| Operating margin | -320.8% | -235.7% |
| Net earnings | −$44.4M | −$39.3M |
| Net margin | -310.8% | -275.6% |
| Operating cash flow | −$43.0M | −$34.0M |
Where the revenue comes from
Coherus Oncology
- Toripalimab: $14.0M (98%)
- Other revenue: $265K (2%)
Questions
Which is bigger, Invivyd or Coherus Oncology?
Invivyd is the larger company: $14.3M of revenue in its latest quarter (Q2 2026) against $14.3M for Coherus Oncology (Q3 2026).
Is Invivyd or Coherus Oncology growing faster?
Coherus Oncology is growing faster (+23% against +21% a year earlier).
Which is more profitable, Invivyd or Coherus Oncology?
Coherus Oncology is more profitable, with an operating margin of -235.7% against -320.8%.
More: Invivyd earnings · how Invivyd makes money · Coherus Oncology earnings · how Coherus Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.